Gm-Csf
CD30-Positive Diffuse Large B-Cell Lymphoma
Medical College of WisconsinPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
270 Active assets in the CD30-Positive Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | A |
Evomela Ruijin Hospital | Phase 4 | BBB |
Axicabtagene Ciloleucel Ruijin Hospital | Phase 4 | BBB |
FILGRASTIM Ruijin Hospital | Phase 3 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →